Evista will be used more to reduce the risk of breast cancer

  Evista will be used more to reduce the risk of breast cancer.

  The FDA just approved this use for postmenopausal women with osteoporosis...or postmenopausal women at high risk for breast cancer.

  Many prescribers already use Evista (raloxifene) as an alternative to tamoxifen to reduce breast cancer risk.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter includes:

  • 12 issues every year, with brief articles about new meds and hot topics
  • 300+ CE courses, including the popular CE-in-the-Letter
  • Quick reference drug comparison charts
  • Access to the entire archive

Already a subscriber? Log in

Volume pricing available. Get a quote